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OBJECTIVES We sought to define the prevalence of cardiac involvement in female patients with
Anderson–Fabry disease (AFD).
BACKGROUND Anderson–Fabry disease is a rare inborn X-linked lysosomal storage disorder. Globotriaosyl-
ceramide (Gb3), the major substrate of the deficient -galactosidase A enzyme, accumulates
progressively in vulnerable cells, including the cardiovascular system. It has been believed that
heterozygous females have less cardiac involvement than hemizygous males with AFD.
METHODS We performed two-dimensional echocardiographic examinations of female patients heterozy-
gous for AFD.
RESULTS Since 1997, a total of 55 female patients (mean age, 39.6 years; range, 6.1 to 70.8 years) with
proven AFD have been investigated prospectively at our hospital. Of these, 13 (23.6%) had
normal left ventricular (LV) geometry and LV mass (LVM). Seven patients (12.7%) had
concentric remodeling, 29 patients (52.7%) concentric LV hypertrophy (LVH), and 6
patients (10.9%) eccentric LVH (2 with subaortic pressure gradients). There was a strong
correlation between age and the severity of LVH (r2  0.905; p  0.0001), and all patients
older than 45 years had LVH. With increasing LVM, there was a significant age-independent
decrease in systolic and diastolic LV function. Mild thickening of the aortic valve leaflets was
present in 25.5% of patients, with the same percentage demonstrating mild thickening of the
mitral valve leaflets. Mild mitral valve prolapse was documented in 10.9% of patients.
CONCLUSIONS Cardiac involvement, with LVH and structural valve abnormalities, is very common and
worsens with age in females who are heterozygous for AFD, and they should therefore be
considered candidates for enzyme replacement therapy. (J Am Coll Cardiol 2002;40:
1668–74) © 2002 by the American College of Cardiology Foundation
Anderson–Fabry disease (AFD) is a rare inborn deficiency
of the lysosomal enzyme -galactosidase A, causing pro-
gressive intracellular accumulation of globotriaosylceramide
(Gb3), the major glycosphingolipid substrate. The incidence
has been estimated to be 1:117,000 male births (1). It affects
different cell types, including myocardial cells and dorsal
root ganglia neuronal cells, as well as endothelial cells and
intimal and smooth muscle cells of the vascular system (2,3).
The intracellular deposits of Gb3 in the heart are similar to
those found in other tissues (4). Cardiac involvement in
hemizygotes is frequent, resulting in hypertrophic changes
of the myocardium, in conduction delays, and in the
thickening of the valves (5–8). Cardiomyopathy can be the
sole manifestation of AFD, and it has been demonstrated
that 3% to 4% of all idiopathic hypertrophic cardiomyopa-
thies may be caused by AFD (9). The prevalence of these
cardiac manifestations has been described in hemizygote
male AFD patients.
Because the genetic abnormalities in AFD are X-linked,
clinical manifestations of AFD in female heterozygotes, as
obligate carriers, have been considered to be rare or mild.
Severe or serious clinical manifestations have been estimated
to affect only 1% of heterozygous females (2). Recently
published data, however, indicate that females are affected
much more commonly than previously believed (10). Ques-
tionnaire studies of patient pedigrees could confirm these
findings (11). The purpose of the present study was to
evaluate the prevalence and severity of cardiac manifesta-
tions of AFD in females genetically proven to be heterozy-
gous for AFD.
METHODS
Based on a large pedigree examination of families with
hemizygous male patients with documented AFD, all pos-
sible female heterozygotes were genetically and enzymati-
cally examined. The inclusion criterion for this prospective
study was a mutation of the -galactosidase A gene con-
firming the diagnosis of AFD. All female AFD patients
received a clinical examination, electrocardiography, blood
pressure (BP) measurements, and detailed echocardiography
with a digital Toshiba 380 SSA Power-Vision ultrasound
system using appropriate transducers (5.0 MHz, 3.5 MHz,
2.5 MHz). The following measurements were made from
M-mode tracings, according to the recommendations of the
American Society of Echocardiography: thickness of the
interventricular septum at end-diastole (IVSd) and at end-
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systole (IVSs); left ventricular (LV) internal cavity diameter
at end-diastole (LVED) and at end-systole (LVES); poste-
rior wall thickness at end-diastole (PWd) and at end-systole
(PWs); end-diastolic aortic root diameter (AoD); and left
atrial diameter at atrial systole (LAD), as described else-
where (12).
Additionally, the thickness of the left atrium at atrial
diastole (LAT) was measured. The LV mass (LVM) was
calculated by the cube formula, modified by Devereux (13),
and indexed to body surface area (BSA) and body height2.7.
Left ventricular hypertrophy (LVH) was considered to be
present if LVM indexed to height was 47 g/m2.7 in
individuals with a body mass index (BMI) below 26 kg/m2
or if LVM indexed to height was 60 g/m2.7 in individuals
with a BMI above 26 kg/m2 (13). Relative wall thickness
(RWT) was calculated as [(IVSd  PWd)/LVED]. Con-
centric remodeling was defined as being present if RWT
was 0.45 and LVM was normal.
Overall LV geometry was classified into one of four
categories: 1) normal (normal LVM and normal RWT); 2)
concentric remodeling (normal LVM and increased RWT);
3) eccentric LVH (increased LVM and septal-to-posterior
wall thickness ratio of 1.5); and 4) concentric LVH
(increased LVM and septal-to-posterior wall thickness ratio
of 1.5). Left ventricular dilation was present if the
BSA-corrected LVED exceeded 32 mm/m2; left atrial
dilation if LAD corrected for BSA exceeded 22 mm/m2,
and aortic root dilation if aortic root exceeded 22 mm/m2
after correction for BSA (14).
The following indices of overall systolic function were
calculated: fractional shortening; fractional long axis short-
ening (LAX) (15); mean velocity of circumferential fiber
shortening corrected for heart rate (mVcfc); pre-ejection
period adjusted for heart rate and gender (PEPc); LV
ejection time adjusted for heart rate (ETc); the ratio of the
non-corrected pre-ejection period to ejection time (PEP/
ET); ejection fraction; and cardiac output (CO) indexed to
BSA (cardiac index [CI]). A CI below 2.0 l/min/m2 was
considered to be reduced. The following indices of overall
diastolic function were also calculated: maximum amplitude
of the E-wave (E-Vmax) and A-wave (A-Vmax); the ratio
of E-max to A-max (E/A ratio); and the isovolumetric
relaxation time (IVRT), the time from aortic valve closure
to mitral valve opening, was obtained by Doppler echocar-
diography (16).
All data were calculated from three cardiac cycles, and
mean values were used for further calculations.
Repeated BP measurements were performed with a Dy-
namap during echocardiographic examination. Systemic
vascular resistance (SVRe: dynescm
5) was estimated as
[(80 times mean arterial BP)/CO].
Patients were divided into two groups according to their
LVM: those with an increased LVM and those with a
normal LVM, based on normative height-corrected values.
Statistical analyses. Statistical analyses were performed
using SPSS version 10.7 for Windows. Data are expressed
as mean  SD or as numbers or percentages of subjects.
Differences between groups were analyzed using the Stu-
dent unpaired t test for continuous variables and the
chi-square test for dichotomous variables. Least-square
linear regression analysis was performed to assess bivariate
correlations between variables. The given corrected r2 are
related to the partial correlation coefficients. Multivariate
analysis was performed to assess co-factorial influences.
Differences were considered to be statistically significant for
p values below 0.05.
RESULTS
Since 1997, a total of 55 female patients with genetically
proven AFD were included in this study. Forty-two of the
55 female subjects were relatives of affected males and were
detected by pedigree examinations. The remaining 13 pa-
tients presented because of classical symptoms of AFD. The
mean age of onset of symptoms was 9.3 years (mostly
neuropathic pain), and the mean age at diagnosis was 40
years. Four patients (7.2%) had fewer than four classic AFD
symptoms, 14 patients (25.5%) four to six symptoms, and 37
patients (67.3%) more than six different symptoms or organ
manifestations dependent on the age of the patients. No
female patients had clinical manifestations limited to the
heart.
The mean age at the time of cardiac examination was
39.6 17.3 years, with a range from 6.1 to 70.8 years. Body
weight ranged from 21 to 96 kg (mean, 63.3 15.3 kg), and
BSA from 0.8 to 2.1 m2 (mean, 1.6  0.2 m2). Mean BMI
was 23.7  4.8 kg/m2 (range, 15.3 to 35.7 kg/m2). Mean
heart rate was 69  14 beats/min (range, 51 to 102
beats/min). Mean systolic BP was 123.6  14.4 mm Hg
(range, 95 to 158 mm Hg) and mean diastolic BP was 70.7
 8.5 mm Hg (range, 53 to 87 mm Hg). The SVRe was
1,935  815 dynescm5. Of the 55 patients, nine (16%)
had arterial hypertension controlled by medication. Seven of
the 55 patients were smokers, and no patients had diabetes
or other diseases that could explain LVH.
General echocardiographic measurements of all 55 female
Abbreviations and Acronyms
AFD  Anderson–Fabry disease
BMI  body mass index
BP  blood pressure
Gb3  globotriaosylceramide
LAD  left atrial diameter
LAT  thickness of the left atrial wall
LAX  fractional long axis shortening
LV  left ventricular/ventricle
LVH  left ventricular hypertrophy
LVM  left ventricular mass
LVM/BSA  left ventricular mass, indexed to body
surface area
LVM/m2.7  left ventricular mass, indexed to height
SVRe  estimated systemic vascular resistance
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patients with AFD are shown in Table 1, and they are
grouped according to absence or presence of an increased
LVM in Table 2. Patients with an increased LVM were
older than patients with a normal LVM and tended to be
more obese, although differences in BSA were not signifi-
cant between the two groups. Patients in these two groups
also differed significantly for AoD, LA cavity diameter
(LAD), LA wall thickness (LAT), and by definition, for all
LVM parameters. The upper 95% confidence limit for age
of patients with a normal LVM was 36.8 years, and the
lower 95% confidence limit for age of patients with an
increased LVM was 39.7 years. Therefore, an age cut-point
of 38.2 years was selected. Above 38.2 years, four of 28
patients were within the normal range of LVM, whereas 24
(85.7%) had an increased LVM. Below 38.2 years of age, 12
of 27 patients (44.4%) had a normal LVM (44.4%), and 15
(55.6%) had an increased LVM. All 25 patients older than
45 years had an increased LVM (Fig. 1). With increasing
LVM there was an increase in LA thickness (F  13.17;
p  0.0007 and r2  0.465) and dimension (F  41.8;
p  0.0001 and r2  0.67).
Of the total population of 55 patients, only 13 (23.6%)
had normal LV geometry; seven patients (12.7%) had
concentric remodeling; 29 (52.7%) had concentric hypertro-
phy; and six (10.9%) had eccentric hypertrophy. Two of the
six patients with eccentric hypertrophy had subaortic gradi-
ents of 15 and 28 mm Hg, respectively.
Multivariate analysis revealed a significant influence only
of age on LVM (F  22.27; p  0.0001; r2  0.905).
Additionally, there was no correlation between LVM and
the presence or absence of residual -galactosidase A
activity within leukocytes or with the gene mutation. Only
two of the 55 (3.6%) female subjects had severely reduced
leucocyte -galactosidase A activity, comparable to findings
in male patients. All others had normal enzyme activity.
Systolic function. Mean indices of systolic function in the
groups of patients with normal versus increased LVM are
presented in Table 3. Classic indices of systolic function,
such as fractional shortening and ejection fraction, did not
differ between the groups, although patients with an in-
creased LVM tended to have a lower CI; but LAX was
significantly reduced in patients with LVH. Additional
indices of systolic function, PEPc and the ratio of PEP/ET,
were prolonged in patients with increased LVM, whereas
ETc did not differ between the groups. Likewise, mVcfc was
decreased with increasing LVM (F  13.51; p  0.001;
r2  0.489). Even in young patients below the cut-off
point of 38.2 years, LVH was associated with reductions
in LAX (50.62  9.5; 95% CI: 44.6 to 56.7 vs. 43.3 
6.7; 95% CI: 38.1 to 48.5; p  0.01) and mVcfc (1.57 
0.26; 95% CI: 1.4 to 1.73 vs. 1.35  0.37; 95% CI: 1.05
to 1.63; p  0.05).
Diastolic function. Indices of LV diastolic function in
patients with normal versus increased LVM are presented in
Table 4. Nearly all measured non-corrected diastolic func-
tion indices differed significantly between patients with a
normal LVM compared with those with LVH. The LVH
was associated with an increase in A-Vmax, and IVRT. The
increase in A-Vmax led to a reduction in the E/A ratio.
Additionally, LVH was associated with a significant in-
crease in T E/A. There was a significant correlation
between increasing LVM and increasing IVRT (r2 0.598;
p  0.0001) and between increasing LVM and decreasing
Table 1. General Echocardiographic Measurements in 55
Female Patients With Anderson–Fabry Disease
Mean  SD Median Range
AoD/BSA (mm) 15.2  3.24 15.09 13–22.5
LAD/BSA (mm) 20.68  3.43 20.25 14.1–27.9
LAT (mm) 4.4  1.14 4.3 2.5–7.5
LVM (g) 235.8  104.2 216.1 57.9–586.9
LVM/BSA (g) 143.2  65 136.7 67.2–391.3
LVM/m2.7 (g) 64.5  34 58.9 28.4–201.1
LVEDV/BSA (ml) 52.9  12.6 51.5 23.3–93.4
LVED/BSA (mm) 27.13  4.63 26.3 19.4–47.5
AoD/BSA aortic root diameter, indexed to BSA; LAD/BSA left atrial diameter,
indexed to BSA; LAT  left atrial wall thickness; LVED/BSA  left ventricular
end-diastolic dimension, indexed to BSA; LVEDV/BSA  left ventricular end-
diastolic volume, indexed to BSA; LVM  left ventricular mass; LVM/BSA 
LVM, indexed to BSA; LVM/m2.7  LVM, indexed to height.
Table 2. Demographic Data for Patients With Increased LVM (n  35) Versus Normal LVM
(n  20)
Increased LVM Normal LVM
Mean  SD
95% Confidence
Limit Mean  SD
95% Confidence
Limit p Value
Age (yrs) 45.4  15.8 39.7–51 29.5  15.1 22.2–36.8  0.001
BSA (m2) 1.67  0.21 1.60–1.75 1.61  0.24 1.47–1.71 NS
BMI (kg/m2) 25.29  4.4 23.7–26.86 20.87  4.0 18.9–22.8  0.001
AoD/BSA (mm) 16.06  2.29 15.28–16.8 14.5  2.27 13.3–15.6 0.023
LAD (mm) 36.57  5.28 34.8–38.4 29.96  3.0 28.46–31.45  0.0001
LAT (mm) 4.82  1.02 4.45–5.18 3.54  0.8 3.13–3.96  0.0001
LVED/BSA (mm) 27.1  3.9 25.75–28.4 26.4  2.9 24.9–27.87 NS
LVEDV (ml) 90.3  22.7 82–98 82.8  7.6 79–86 NS
LVM (g) 292.4  102 257.3–327 154.6  24.1 142.5–166.5  0.0001
LVM/BSA (g) 176.3  67.8 152.9–199.6 94.2  12.6 87.9–100.5  0.0001
LVM/m2.7 (g) 81.7  35.5 69.5–93.9 38.8  6.47 35.6–42.0  0.0001
BMI  body mass index; BSA  body surface area; other abbreviations as in Table 1.
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E/A ratio (r2  0.499; p  0.0001). Even after adjustment
for age, there was still a reduction in the E/A ratio in
patients with an increased LVM compared with patients
with a normal LVM (F 18.13; p 0.0001; r20.509).
Furthermore, an increase in LAD and LAT was accompa-
nied by an increase in IVRT (F  12.4; p  0.001; r2 
0.671 and F  7.17; p  0.01; r2  0.44) and a decrease in
E/A ratio (F  24.35; p  0.0001; r2  0.572 and F 
12.17; p  0.001; r2  0.455).
Of the 55 patients investigated, 27 (49.1%) had an E/A
ratio above 1.5, while 23 patients (41.9%) had a ratio
between 1.5 and 1.0, and five patients (9%) had a ratio
below 1.0. Increasing mass was correlated with a decrease in
the E/A ratio (F 6.546; p 0.014). This decrease in E/A
ratio could be noted as dependent on age and LVM (F 
4.980; p  0.012), and on age, LVM, and IVRT corrected
for heart rate (IVRTc) (F  3.316; p  0.02). There was a
significant correlation between IVRTc and the E/A ratio
(F  6.621; p  0.016; r2  0.444). Patients with a
severely reduced E/A ratio below 1.0 had a significantly
higher LVM than those with a normal E/A ratio (83.06 
13.4 g; 95% CI: 66.4 to 99.7 g vs. 64.2  36.5 g; 95% CI:
Figure 1. Left ventricular mass (LVM) corrected for height plotted against age in 55 patients. There are two benchmark lines included: one at 47 g/m2.7,
indicating the normal limits of LVM. Above 38.2 years of age, 25 of 28 (89.3%) patients had an increased LVM, as did 25 of 25 (100%) patients above
45 years of age. Below 38 years of age, 12 of 27 (44.4%) patients had a normal LVM.
Table 3. Systolic Function in Patients With Increased LVM (n  35) Versus Normal LVM
(n  20)
Increased LVM Normal LVM
Mean  SD
95% Confidence
Limit Mean  SD
95% Confidence
Limit p Value
FS (%) 40.6  8.5 37.6–43.6 39.6  6.4 36.6–42.7 NS
LAX (%) 42  7.2 39.5–44.6 50.2  8.8 45.9–54.4  0.001
mVcfc (circ/s) 1.33  0.39 1.18–1.47 1.5  0.32 1.33–1.69 0.049
PEPc (ms) 126  20.6 118.6–133.4 115.2  14.8 107–122.6 0.029
ETc (ms) 414.7  27.2 405.1–424.4 419.9  23.9 408.1–431.8 NS
PEP/ET 0.324  0.05 0.299–0.349 0.287  0.062 0.256–0.301 0.048
EF (%) 69.2  10.3 65.6–72.9 70.3  8.3 66.3–74.2 NS
CI (l/min/m2) 2.42  0.74 2.16–2.69 2.8  0.99 2.31–3.3 NS
CI cardiac index; EF ejection fraction; ETc ejection time, adjusted for heart rate and gender; FS fractional shortening;
LAX long axis shortening; LVM left ventricular mass; mVcfcmean velocity of circumferential fiber shortening, corrected
for heart rate; PEPc pre-ejection period, adjusted for heart rate and gender; PEP/ET ratio of pre-ejection period to ejection
time.
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53.8 to 74.6 g; p  0.035). Eight of 27 patients with
reduced E/A ratio and reduced CI and LVH were in New
York Heart Association (NYHA) functional class III to IV,
although having normal or minimally reduced indices of
systolic function.
Additional echocardiographic findings. There was thick-
ening of the aortic valve leaflets in 14 patients (25.5%) and
mild mitral valve thickening combined with very mild
insufficiency in 14 others (25.5%). Six patients (10.9%) had
mild mitral valve prolapse. No patient had a gradient across
the aortic valve of more than 20 mm Hg. Patients with
aortic valve thickening were significantly older than those
without (54.9  13.4 years vs. 35.49  16 years; p 
0.0001), as were patients with mitral valve thickening and
regurgitation (56.5  12.9 years vs. 34.9  15.4 years; p 
0.0001). Both the aortic and mitral valves were affected in
seven patients (12.7%); these seven patients were signifi-
cantly older than those who were not affected (64.2  6.6
years vs. 37.0 15.8 years; p 0.0001). There was a strong
correlation between LVM increase and bi-valvular manifes-
tations of AFD (F  58.23; p  0.0001; r2  0.724).
DISCUSSION
In light of new therapeutic strategies for treatment of
lysosomal storage diseases with enzyme replacement ther-
apy, it is of major interest to know who might be affected.
No previous studies have focused solely on the presence of
cardiac involvement in female heterozygotes; prevalence
data have been presented combined with data from hem-
izygote male patients (5,7,17). One reason for this might be
that female patients, except those who presented with severe
clinical symptoms of heart failure, have not been examined
systematically for cardiac involvement. This lack of atten-
tion to female subjects was probably driven by the common
belief that heterozygous “carriers” of an X-linked recessive
disease are not likely to be affected as seriously as hemizy-
gote males (2). The present study shows that the prevalence
of cardiac involvement in heterozygote females is high and
might be as high as in males. This is in contrast to previous
published data (11). It should therefore be considered that
AFD follows X-linked dominant rather than recessive
transmission.
One major difference between male and female patients
with AFD is the degree of residual activity of
-galactosidase A. Female patients usually present with low
to even normal residual enzyme activity. Nevertheless, even
female patients with normal plasma enzyme levels can show
a number of clinical symptoms of AFD, and they may have
severe cardiac involvement.
All the women investigated who were over 45 years of age
had LVH, and their hypertrophy was not related to arterial
hypertension or other diseases. Those nine females with
controlled arterial hypertension have been treated mainly
with diuretics and angiotensin-converting inhibitors be-
tween three and 18 years. Three of them started treatment
before the final diagnosis of AFD had been established.
Cardiac involvement below 38 years of age was more
variable. The youngest female patient with LVH was 14
years old. The severity of hypertrophy appears to progress
with age, in agreement with previous data (5,7), and LVH
apparently occurs 10 to 15 years later in heterozygote
females than in hemizygote males. There were four female
patients with severe cardiomyopathy (LVM 150 g/m2.7)
who were older than 66 years (Fig. 1). They were all in
NYHA functional class IV, and one had reduced leukocyte
-galactosidase activity.
The major cardiac abnormality was LVH. Only 23.6% of
the female patients had normal LV geometry and mass.
Concentric hypertrophy, with or without very mild cavity
dilation, appears to be the most common abnormality
(52.7%), followed by concentric remodeling (12.7%) and
eccentric hypertrophy (10.9%). In addition to increased wall
thickness of the LV, there was an increase in LA thickness
and cavity diameter. The increased LAT is consistent with
the increased LV thickness and likely indicates atrial dep-
osition of Gb3. Furthermore, it is known that increased
LVM in patients with hypertension correlates with in-
creased LAD, indicating an impaired LV diastolic filling
(18).
Classic indices of overall systolic function were normal, as
has previously been reported in males (5,7,17). However,
with increasing mass we observed a decrease in long axis
shortening and mean velocity of circumferential fiber short-
ening. Decreased long axis shortening with preserved frac-
tional shortening is also known to occur in severe LVH due
to pressure overload (15).
Additionally, a disturbed long axis function reflects early
diastolic dysfunction when systolic function remains normal
Table 4. Diastolic Function in Patients With Increased LVM (n  35) Versus Normal LVM
(n  20)
Increased LVM Normal LVM
Mean  SD
95% Confidence
Limit Mean  SD
95% Confidence
Limit p Value
E-Vmax (m/s) 0.87  0.19 0.81–0.94 0.93  0.18 0.84–1.01 NS
A-Vmax (m/s) 0.63  0.12 0.59–0.67 0.55  0.16 0.47–0.63 0.046
E/A ratio 1.44  0.48 1.27–1.61 1.77  0.52 1.51–2.02 0.019
IVRT (ms) 101.3  23.7 92.06–110.4 88.7  14.1 81.7–95.7 0.049
A -Vmax  peak velocity of mitral A-wave; E/A ratio  ratio of E-wave Vmax to A-wave Vmax; E-Vmax  peak velocity of
Mitral E-wave; IVRT  isovolumetric relaxation time; LVM  left ventricular mass.
1672 Kampmann et al. JACC Vol. 40, No. 9, 2002
Cardiac Manifestations of AFD in Heterozygous Females November 6, 2002:1668–74
(19,20). Likewise, an increase in LVM was also associated
with a prolonged PEPc and an increase in the PEP/ET
ratio, which may additionally indicate a reduced rate of
increase of LV filling pressure during isovolumetric systole
(LV dP/dt). These findings were age independent, as
demonstrated by comparisons of patients with normal mass
or LVH below the age of 38 years. Although all compared
measurements of systolic function were within the normal
ranges, there were significant differences between both
groups. Nevertheless, patients with AFD cardiomyopathy
without clearly abnormal hemodynamic functions (i.e.,
without pressure or volume overload) can be distinguished
from AFD patients with normal hearts by the presence of
depressed ejection phase indices and lower mVcf values (21).
Of the investigated patients with LVH, 22.8% (8 of 35) were
in NYHA functional class III or IV, and their dyspnea was not
related to other AFD-related organ involvement.
Although most parameters of diastolic function also
remained within the normal range, LA cavity size and wall
thickness were increased. In fact, there was a good correla-
tion between increased LA wall thickness and cavity size
and reduced diastolic function parameters. Nearly all non-
corrected parameters of diastolic function, however, showed
significant differences between patients with normal LVM
and those with increased LVM. Even after correction for
age and heart rate, differences in IVRT, A-Vmax, and the
E/A ratio remained. This result contrasts with the results of
a previously published study (5), in which only three of the
17 patients had, by our definition, severely increased LVM.
Likewise, the mean age of the females studied by Linhart et
al. (5) was 35  19 years, while the mean age of the
hemizygotes in that study was 39  10 years. In our study
population, five of the patients (9%) with a significantly
increased LVM had evidence of diastolic dysfunction, as
indicated by an E/A ratio below 1.0 and a prolonged IVRT.
An increase in LVM may lead to diastolic dysfunction of
the LV independent of the age of the patient and may,
thereby, result in restrictive cardiomyopathy (22–24). Al-
though classic infiltrative cardiomyopathies are frequently
restrictive, the infiltrative cardiomyopathy associated with
AFD seems to be different. By contrast with other cardio-
myopathies (e.g., cardiac amyloidosis), where there is inter-
stitial infiltration, in AFD the lipid accumulation is intra-
lysosomal; furthermore, the amount of Gb3 deposited in the
myocytes is 1% of the LVM (11 mg/g heart wet weight)
(24, 25). Therefore, there appears to be a true increase in
LV myocyte mass in AFD cardiomyopathy. It is known that
an increase in LVM can result in impaired ventricular
compliance and increased filling pressures, leading to the
restriction of diastolic filling and symptoms of congestive
heart failure. Interpretation of the given data indicates an
impaired compliance, a reduced rate of increase of filling
pressure during isovolumetric systole (LV dP/dt), and an
increased filling pressure in all those patients with the most
severe cardiac involvement.
The present study also showed frequent valvular abnor-
malities, mostly consisting of thickening of the aortic and
mitral valves. The prevalence of mitral and aortic valve
abnormalities increased with age. Thickening of the aortic
valve was not observed below the age of 23 years, and mitral
valve thickening was not observed below 33 years of age.
Combined mitral and aortic valve thickening was not
observed below the age of 54 years. Furthermore, this study
did not confirm the high incidence of mitral valve prolapse
previously reported by others (7,26). Those patients with
mitral valve prolapse had no or only very mild regurgitation.
A high incidence of aortic root dilation has been described
previously in severely affected male patients (7,17). In our
female study population, the aortic root diameter was
significantly larger in patients with an increased LVM than
in patients with a normal LVM; but there was only one
patient in whom the BSA-indexed AoD exceeded 22
mm/m2, and this patient had eccentric LVH. Aortic root
dilation appears, therefore, to be less frequent in female
heterozygotes than in male hemizygotes.
Study limitations. The present study has several limita-
tions. Even though its single-observer design has the ad-
vantage of limiting interobserver variability, it has the
disadvantages inherent in a single-observer study. Parame-
ters presented in this study were obtained non-invasively,
and though they were therefore available from more pa-
tients, it is recognized that there are more sophisticated
parameters available for describing left ventricular diastolic
function by using more invasive monitoring techniques. Ad-
ditionally, the use of these frequently reported parameters offers
the possibility of comparing our data in AFD patients with
data from other hypertrophic cardiomyopathies.
Conclusions. This is the first study to demonstrate the
high incidence of cardiac involvement in females heterozy-
gous for AFD. The most frequent cardiac structural anom-
aly was concentric LVH, followed by cardiac remodeling
and eccentric hypertrophy. The structural changes were
highly correlated with the age of the patients, and the
increasing LVM caused impairment of systolic and diastolic
function. Valvular abnormalities, such as aortic or mitral
leaflet thickening, while frequent, were mild. Mitral valve
prolapse was found not to be as frequent as previously
reported. Female patients with AFD have equally severe
cardiac involvement and should therefore be considered for
enzyme replacement therapies.
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